Rhythm Leans On Imcivree Rare Disease Commercialization For New Indication

 
• By Alaric DeArment
Rhythm Pharmaceuticals won FDA approval for Imcivree in Bardet-Biedl syndrome • Source: Shutterstock

More from Rare Diseases

More from Scrip